Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment

  • Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting
  • US analysis of long-term financial impact when switching to biosimilar etanercept also presented, modeling significant cost savings for health systems
  • Sandoz is the pioneer and a global leader in biosimilars, with eight approved biosimilars worldwide and more than 10 in the pipeline

Holzkirchen, November 12, 2019 – Sandoz, a Novartis division and a global …

/by

New Novartis PREVENT data show Cosentyx® delivers early relief in axial spondyloarthritis

  • 42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores through Week 16; improvements continued through Week 52[1]
     
  • PREVENT is the largest ever study of a biologic in patients with nr-axSpA and underscores Novartis leadership in rheumatology[1]
     
  • There are approximately 1.7 million patients with nr-axSpA in the EU and US[2]
     
  • PREVENT adds to 5-year evidence in ankylosing spondylitis (AS) and is a step forward in providing patients with …
/by

Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment

  • Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting
  • US analysis of long-term financial impact when switching to biosimilar etanercept also presented, modeling significant cost savings for health systems
  • Sandoz is the pioneer and a global leader in biosimilars, with eight approved biosimilars worldwide and more than 10 in the pipeline

Holzkirchen, November 12, 2019 – Sandoz, a Novartis division and a global …

/by

Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment

  • Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting
  • US analysis of long-term financial impact when switching to biosimilar etanercept also presented, modeling significant cost savings for health systems
  • Sandoz is the pioneer and a global leader in biosimilars, with eight approved biosimilars worldwide and more than 10 in the pipeline

Holzkirchen, November 12, 2019 – Sandoz, a Novartis division and a global …

/by